India, Jan. 1 -- Civil society organisations urge Indian drug regulator to put vaccine trial data in public domain

The concerned subject expert committee (SEC) recommended January 1, 2021 to the Drug Controller General of India (DCGI) that emergency authorisation be granted to Serum Institute of India's (SII) vaccine for the novel coronavirus disease (COVID-19).

SII is manufacturing the vaccine with AstraZeneca plc and University of Oxford. It was granted restricted approval by the British regulator December 30, 2020.

The recommendation, with several unknown conditions, by the Indian SEC came after an eight-hour meeting. DCGI VG Somani will take the final call. On the last day of 2020, he said the country might have a "happy new year" ...